Publish in OALib Journal
APC: Only $99
The authors herein report the case of a 67-year-old woman with
metastatic renal-cell carcinoma (RCC), who has had a sustained clinical and
stable radiological response to long-term therapy with an oral multi-targeted
tyrosine kinase inhibitor (TKI), sunitinib
with minimal lasting toxicity.